Concurrent chemoradiotherapy in limited-stage small-cell lung cancer. Results of a pilot study

A. Radkowski; S. Korzeniowski; B. Sas-Korczyńska; K. Malecki; J. Skołyszewski

doi:10.1016/S1507-1367(99)70307-X

Vol 4, No 1 (1999)

Original papers

Published online: 1999-01-01

Submitted: 1999-01-07

View PDF

Download PDF file

Get Citation

Concurrent chemoradiotherapy in limited-stage small-cell lung cancer. Results of a pilot study

A. Radkowski, S. Korzeniowski, B. Sas-Korczyńska, K. Malecki, J. Skołyszewski

DOI: 10.1016/S1507-1367(99)70307-X

Rep Pract Oncol Radiother 1999;4(1):3-8.

Vol 4, No 1 (1999)

Original papers

Published online: 1999-01-01

Submitted: 1999-01-07

Abstract

Between January 1994 and February 1998, 32, limited-stage small-cell lung cancer patients were treated with concurrent chemoradiotherapy. Follow-up time ranged from 4 to 34 months, (median 14 months). Complete regression was obtained in 22 of the 30 patients, who received at least four courses of EP chemotherapy and a tumour dose of 50 Gy or more. In all, 2-year actuarial disease-free survival was 21 %. Brain metastases occurred in 8 (36.4 %) patients with CR, in 5/7 (71.4 %) patients without prophylactic cranial irradiation (PCI) and in 3/15 (20 %) patients after PCI. The survival rate was lower in patients with PCI, in Whom chest irradiation was started later than one month from the beginning of course 1 of EP chemotherapy. We have suggested a modification of the treatment protocol.